Table 1.
Laboratory results.
| Patient 1 | Patient 2 | Reference range | |
|---|---|---|---|
| Baseline | |||
| TSH | 0.08 | <0.03 | 0.38–5.33 mIU/mL |
| fT4 | 24.84 | 20.47 | 7.72–17.63 pmol/L |
| TT3 | 2.3 | 2.22 | 0.86–2.39 nmol/L |
| TPOAb | 0.6 | 777.4 | 0–9 IU/mL |
| TGAb | <0.9 | 275.3 | 0–4 IU/mL |
| TRAb | <0.1 | 0.2 | <1 IU/L |
| ESR | 103 | 17 | 0–30 mm/h |
| CRP | 135 | 1 | <6 mg/L |
| SARS-CoV-2 IgG II Quant | 1271.3 | 245.4 | <50 AU/mL |
| Follow up | 8th week | 8th week | |
| TSH | 1.93 | 2.88 | 0.38–5.33 mIU/mL |
| fT4 | 10.55 | 9.27 | 7.72–17.63 pmol/L |
| TT3 | NA | 1.64 | 0.86–2.39 nmol/L |
| TPOAb | 0.5 | 665.3 | 0–9 IU/mL |
| TGAb | <0.9 | 246.3 | 0–4 IU/mL |
| ESR | 17 | 16 | 0–30 mm/h |
| CRP | 2 | NA | <6 mg/L |
Abbrevations: TGAb, anti-thyroglobulin antibody; TPOAb, thyroid peroxidise antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TT3, total triiodothyronine; fT4, free thyroxine; NA, not assessed; TRAB, TSH receptor antibodies; TSH, thyroid-stimulating hormone; SARS-CoV-2 IgG II Quant: IgG antibodies against the spike receptor-binding domain (RBD) of SARS-CoV-2.